Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 6, 2015
(Thomson Reuters ONE) -
CellaVision AB (publ) held its Annual General Meeting today, 6 May 2015, in
Lund. The meeting resolved upon the following:
* Payment of dividend in the amount of SEK 1 per share with 8 May 2015 as
record date, meaning that payment is expected to be made on 13 May 2015.
* Discharge from liability for the members of the Board of Directors and the
President and CEO.
* Re-election of Lars Gatenbeck, Christer Fåhraeus, Roger Johanson, Torbjörn
Kronander, Anna Malm Bernsten and Niklas Prager as members of the Board of
Directors. Election of Åsa Hedin as a new member of the Board of Directors.
Re-election of the auditor.
* Resolution on remuneration for the members of the Board of Directors and the
auditor.
* Resolution on an incentive program for the company management. Those
eligible are the CEO and members of the executive management.
More detailed information concerning the resolutions passed at the general
meeting of shareholders is available in Swedish only.
CEO Zlatko Rihter's address to the meeting is available at the Investor pages at
CellaVision's website (Swedish).
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB.
Phone: +46 70 535 44 44, e-mail: lars.gatenbeck(at)lifemedical.se
Zlatko Rihter, CEO, CellaVision AB.
Phone: +46 733 62 11 06, e-mail: zlatko.rihter(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. In most countries sales are
via global partners. Products are sold directly in the Nordic countries and via
subsidiaries in the US, Canada and Japan. In 2014 sales were SEK 217 million and
sales continue to increase, with a growth target of at least 15 % per year over
an economic cycle. CellaVision's registered office is in Lund, Sweden. The share
is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
Publication
The information in this press release comprises such information as CellaVision
AB (publ) is required to publish in accordance with the Securities Market Act
and/or the Financial Instruments Trading Act. This information was released for
public disclosure on May 7, 2015 at 08:20 CET.
Press release as pdf:
http://hugin.info/132164/R/1919486/687275.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via GlobeNewswire
[HUG#1919486]
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2015 - 08:21 Uhr
Sprache: Deutsch
News-ID 391655
Anzahl Zeichen: 3499
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 140 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 6, 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
